文献速递血栓与止血

JAK2突变克隆性造血与静脉血栓栓塞相关

JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism.
PubMed 文献 · Blood · 2024-01-01

在UK Biobank超过40万样本中评估CHIP与静脉血栓栓塞(VTE)的关联。CHIP整体与 incident VTE modestly相关(HR 1.17),但与 prevalent VTE 无显著关联;JAK2突变CHIP与 prevalent VTE(OR 6.58)和 incident VTE(HR 4.2)均高度相关,排除潜在未诊断MPN后仍显著。

要点

  • CHIP整体与 incident VTE 的 HR 为 1.17(95%CI 1.09-1.3),与 prevalent VTE 无显著关联(OR 1.02)。
  • JAK2突变CHIP与 prevalent VTE 的 OR 为 6.58(95%CI 2.65-16.29),与 incident VTE 的 HR 为 4.2(95%CI 2.18-8.08)。
  • TET2突变CHIP与 incident VTE 的 HR 为 1.33(95%CI 1.05-1.69)。

核心结论

  • 大多数CHIP个体血栓风险未改变,但JAK2突变CHIP个体VTE风险显著升高。

研究设计与样本

  • 基于UK Biobank超过40万样本,评估CHIP与 prevalent 和 incident VTE 的总体及基因型特异性关联。

主要发现

  • CHIP与 incident VTE 的 HR 为 1.17(95%CI 1.09-1.3;P=.002),与 prevalent VTE 的 OR 为 1.02(95%CI 0.81-1.23;P=.81)。
  • TET2突变CHIP与 incident VTE 的 HR 为 1.33(95%CI 1.05-1.69;P=.02)。
  • JAK2突变CHIP与 prevalent VTE 的 OR 为 6.58(95%CI 2.65-16.29;P=4.7×10⁻⁵),与 incident VTE 的 HR 为 4.2(95%CI 2.18-8.08;P=1.7×10⁻⁵)。
  • 排除基于实验室参数的潜在未诊断MPN后,JAK2突变CHIP与VTE的关联仍显著。
  • JAK2突变CHIP与VTE关联更强但比杂合因子V Leiden和杂合凝血酶原基因突变更少见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is common among older individuals, but provoking factors are not identified in many cases. Patients with myeloid malignancies, especially myeloproliferative neoplasms (MPNs), are at increased risk for venous thrombosis. Clonal hematopoiesis of indeterminate potential (CHIP), a precursor state to myeloid malignancies, is common among older individuals and may similarly predispose to venous thrombosis. We evaluated overall and genotype-specific associations between CHIP and prevalent and incident VTE in >400 000 samples from the UK Biobank. CHIP was modestly associated with incident VTE with a hazard ratio (HR) of 1.17 (95% confidence interval [CI], 1.09-1.3; P = .002) but was not significantly associated with prevalent VTE with an odds ratio (OR) of 1.02 (95% CI, 0.81-1.23; P = .81). TET2-mutant CHIP was associated with incident VTE with a HR of 1.33 (95% CI, 1.05-1.69; P = .02). JAK2 mutations were highly associated with both prevalent and incident VTE risk, with an OR of 6.58 (95% CI, 2.65-16.29; P = 4.7 × 10-5) and a HR of 4.2 (95% CI, 2.18-8.08; P = 1.7 × 10-5), respectively, consistent with the thrombophilia associated with JAK2-mutant MPN. The association between JAK2-mutant CHIP and VTE remained significant after excluding potential undiagnosed MPN based on laboratory parameters. JAK2-mutant CHIP was more strongly associated with VTE but was less common than heterozygous factor V Leiden and heterozygous prothrombin gene mutation. These results indicate that most individuals with CHIP do not have an altered risk of thrombosis, but individuals with JAK2-mutant CHIP have a significantly elevated risk of VTE.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zon RL, Sekar A, Clapham K, et al. JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism. Blood. 2024. PMID: 39102652. doi:10.1182/blood.2024024187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。